Mar­i­nus’ IV seizure drug faces ef­fi­ca­cy ques­tions as Ph3 con­tin­ues past in­ter­im analy­sis

Mar­i­nus Phar­ma­ceu­ti­cals is con­tin­u­ing a Phase 3 tri­al of an in­tra­venous treat­ment for pro­longed seizures past an in­ter­im analy­sis, which sug­gests that the study did not meet sta­tis­ti­cal sig­nif­i­cance.

The com­pa­ny is study­ing an IV for­mu­la­tion of ganax­olone for re­frac­to­ry sta­tus epilep­ti­cus — pro­longed seizures that do not re­spond to two lines of oth­er med­ica­tions. Mar­i­nus mar­kets an oral sus­pen­sion of ganax­olone as Ztalmy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER